• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Longevity

Top aging expert says these 4 FDA-approved drugs hold promise for extending life

By
Alexa Mikhail
Alexa Mikhail
Senior Reporter, Fortune Well
Down Arrow Button Icon
By
Alexa Mikhail
Alexa Mikhail
Senior Reporter, Fortune Well
Down Arrow Button Icon
October 29, 2024, 5:02 AM ET
“The evidence that we're looking for is from clinical trials, not if it cured an animal and not if people who took it told me that they're doing better,” says Dr. Nir Barzilai.
“The evidence that we're looking for is from clinical trials, not if it cured an animal and not if people who took it told me that they're doing better,” says Dr. Nir Barzilai. Longevity Investors Conference / David Biedert

There’s not a cure-all drug to help us live longer. 

Recommended Video

Dr. Nir Barzilai, the director of the Institute for Aging Research at the Albert Einstein College of Medicine and board member at The American Federation for Aging Research (AFAR), predicts it will take a few decades to see impactful gerotherapeutics—drugs that counter the aging process—for the average person. The key is discovering safe and effective drugs that target mechanisms, like inflammation and cellular damage, that lead to aging. 

“The evidence that we’re looking for is from clinical trials, not if it cured an animal and not if people who took it told me that they’re doing better,” he told Fortune at the Longevity Investors Conference last month in Gstaad, Switzerland. He says people must be careful not to give into false, baseless promotions of efficacy: “Many people are making decisions based on hope rather than on promise. If you hear something really exciting, say, ‘Okay, what’s the data? Did you do a clinical study?’” 

A successful gerotherapy, Barzilai says, will do four things: 

  1. Target the hallmarks of aging
  2. Extend health span by reducing the risk of disease at the end of life
  3. Be tested for safety and efficacy on hundreds, possibly thousands of people in clinical trials 
  4. Influence all-cause mortality 

Geroscience has a long way to go, but there are four FDA-approved drugs that have shown promise to “target the process of aging,” Barzilai says. While not approved as anti-aging treatments, these drugs score the highest on his 12-point scale assessing their longevity potential.

“Some of those drugs have been decreasing hospitalization, death, and long COVID, making the point that although some of them are designed for diabetes, they affect immunity,” he said at a lecture at the Longevity Investors Conference. “They affect immunity, and, maybe, they affect the whole body’s ability to be resilient to a severe disease in the end.” 

Here are the four: 

GLP-1s 

Barzilai and other experts have pointed to GLP-1s (Ozempic, Wegovy), the wildly popular class of drugs targeting diabetes and obesity, as potential longevity boosters.

“It was developed for diabetes, and it was shown to actually decrease obesity,” says Barzilai, who adds there is evidence of a reduced risk of heart disease, kidney disease, Parkinson’s, and Alzheimer’s. The drugs scored a 10 out of 12 on the gerotherapeutic scale. “It actually targets the mechanisms of aging.”

Dr. Douglas Vaughan, a professor of medicine at Northwestern University and director of the Potocsnak Longevity Institute, previously told Fortune that extensive research on animals has found calorie restriction to be the most effective way to extend life. 

GLP-1s suppress appetite and have been shown to improve blood sugar levels for those with type 2 diabetes. They may also play a larger role in chronic disease mitigation and reducing inflammation, although more long-term evidence is needed to also ensure that you can lose weight but not muscle weight. 

SGLT2 inhibitors

SGLT2 inhibitors, blood-sugar-lowering drugs, are the only drugs on the list scoring a perfect score on Barzilai’s scale. The inhibitors are typically prescribed for those with type 2 diabetes to remove sugar from the kidneys through urine, which lowers blood sugar levels. 

The drugs, while used to treat diabetes, show promise in reducing the risk of age-related diseases and kidney disease, by reducing oxidative stress and inflammation, and improving heart health and even cognition. New research also suggests the inhibitors may reduce the risk of dementia in people with type 2 diabetes after longer-term use.  

Bisphosphonates 

Bisphosphonates, scoring 11 out of 12, treat osteoporosis, which affects 10 million Americans. They are prescribed to those with the condition to reduce the loss of bone density. 

“Since their introduction to clinical practice, bisphosphonates have transformed the clinical care of an array of skeletal disorders,” reads one paper published in the Mayo Clinic Proceedings. 

Observational studies also suggest the drugs reduce mortality. One analysis found people using bisphosphonates were 15% less likely to die than nonusers after a 2.8 year follow up. 

Metformin 

Metformin, which has been around for 60 years, is the most prescribed type 2 diabetes drug. Studies also show that the drug, scoring an 11 out of 12 as a gerotherapeutic, targets hallmarks of aging like cellular senescence by protecting DNA, decreasing inflammation, and improving insulin sensitivity, according to a paper in the Aging and Disease journal.  

However, researchers note that while metformin makes the list as a possible anti-aging drug, the results in nondiabetic patients are not as understood. 

More broadly, while research suggests that any of these drugs may target mechanisms of aging, they are not approved for anti-aging alone, and eligible candidates are those who typically present with one or more preexisting conditions. 

“Every drug has some contraindication or side effects,” Barzilai says. “You just have to know who’s the right patient.” 

People should speak with a provider about their health status, drug interactions, and whether any of these are an appropriate remedy. And still, the main pillars of healthy aging are lifestyle changes, especially for healthy, young people, Barzilai says. 

“Not every drug that’s good for old people is good for young people, but the things that are good for young and old are exercise, diet, sleep, and social connectivity,” Barzilai says. “You can always maximize that.” 

Still, he says it won’t be lifestyle alone that will be able to dramatically extend human life span.

For more on healthy aging:

  • Will you live to 150? Here’s what 5 geneticists and aging researchers say
  • The strange reason why your body ages most rapidly between 44 and 60—and how to combat it
  • Your flexibility might predict your life span. Take this test to find out
  • Deepak Chopra says inflammation is ‘the number one pandemic of our times.’ He suggests these 5 habits to help reduce it
Join us at the Fortune Workplace Innovation Summit May 19–20, 2026, in Atlanta. The next era of workplace innovation is here—and the old playbook is being rewritten. At this exclusive, high-energy event, the world’s most innovative leaders will convene to explore how AI, humanity, and strategy converge to redefine, again, the future of work. Register now.
About the Author
By Alexa MikhailSenior Reporter, Fortune Well
LinkedIn iconTwitter icon

Alexa Mikhail is a former senior health and wellness reporter for Fortune Well, covering longevity, aging, caregiving, workplace wellness, and mental health.

See full bioRight Arrow Button Icon

Latest in

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Latest in

Current refi mortgage rates report for April 30, 2026
Personal FinanceReal Estate
Current refi mortgage rates report for April 30, 2026
By Glen Luke FlanaganApril 30, 2026
30 minutes ago
Mortgage rates today, April 30, 2026
Personal Financemortgages
Mortgage rates today, April 30, 2026
By Glen Luke FlanaganApril 30, 2026
30 minutes ago
Current ARM mortgage rates report for April 30, 2026
Personal FinanceReal Estate
Current ARM mortgage rates report for April 30, 2026
By Glen Luke FlanaganApril 30, 2026
30 minutes ago
Aerie built a $2 billion brand by rejecting Victoria’s Secret’s old playbook. Now it wants to win the AI backlash.
C-SuiteRetail
Aerie built a $2 billion brand by rejecting Victoria’s Secret’s old playbook. Now it wants to win the AI backlash.
By Phil WahbaApril 30, 2026
31 minutes ago
The debt crisis Congress has been ignoring could cost the average U.S. household $18,000 a year, according to a Brookings analysis
EconomyFinance
The debt crisis Congress has been ignoring could cost the average U.S. household $18,000 a year, according to a Brookings analysis
By Shawn TullyApril 30, 2026
31 minutes ago
Google Cloud revenue is now 18% of Alphabet’s business. Is this the beginning of the end of Google’s search identity?
Big TechGoogle
Google Cloud revenue is now 18% of Alphabet’s business. Is this the beginning of the end of Google’s search identity?
By Alexei OreskovicApril 29, 2026
6 hours ago

Most Popular

Apple cofounder Ronald Wayne—whose stake would be worth up to $400 billion had he not sold it in 1976—says that at 91, he has no regrets
Success
Apple cofounder Ronald Wayne—whose stake would be worth up to $400 billion had he not sold it in 1976—says that at 91, he has no regrets
By Preston ForeApril 27, 2026
3 days ago
‘Take the money and run’: Johns Hopkins economist Steve Hanke on why the UAE quit OPEC
Energy
‘Take the money and run’: Johns Hopkins economist Steve Hanke on why the UAE quit OPEC
By Shawn TullyApril 29, 2026
1 day ago
‘The cost of compute is far beyond the costs of the employees’: Nvidia executive says right now AI is more expensive than paying human workers
AI
‘The cost of compute is far beyond the costs of the employees’: Nvidia executive says right now AI is more expensive than paying human workers
By Sasha RogelbergApril 28, 2026
2 days ago
Jamie Dimon gets candid about national debt: ‘There will be a bond crisis, and then we’ll have to deal with it’
Economy
Jamie Dimon gets candid about national debt: ‘There will be a bond crisis, and then we’ll have to deal with it’
By Eleanor PringleApril 29, 2026
21 hours ago
‘They left me no choice’: Powell isn’t going anywhere—blocking Trump from another Fed appointee
Banking
‘They left me no choice’: Powell isn’t going anywhere—blocking Trump from another Fed appointee
By Eva RoytburgApril 29, 2026
12 hours ago
More than two-thirds of U.S. schools say they’re unable to afford the cost of student free lunch—and MAHA’s dietary guidelines may make it worse
Economy
More than two-thirds of U.S. schools say they’re unable to afford the cost of student free lunch—and MAHA’s dietary guidelines may make it worse
By Sasha RogelbergApril 29, 2026
22 hours ago